Navigation Links
NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sector's Recent Market Decline
Date:12/16/2013

NW Bio's Phase III trial is also potentially powered for the secondary endpoint of overall survival (OS), and it has an interim analysis devoted solely to reviewing the size of the trial, which can enable increasing the size of the trial if desired.  In addition to all these measures, the trial has built-in analyses of specified subsets of the patients in the trial.

In contrast, the Competitor's trial was a 124-patient Phase II trial.  It was approved by only one regulator (FDA) and conducted only in the US.  According to the Competitor's description of its trial, the trial was designed with a target of 9 months' difference in overall survival between the treated arm and the control arm in the trial.  It is unclear to what extent a cushion was built into the statistical powering in this trial design.  

Company Positioning Differences.  NW Bio has undertaken years of work and devoted extensive resources to building many chances for success.  The Company now has two potential major value-driver programs under way in parallel:  its lead Phase III trial with DCVax-L for GBM brain cancer, and its large (60 patient) Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors with a particularly significant efficacy endpoint (regression of existing inoperable tumors). 

Each of these parallel programs are expected to have ongoing catalysts throughout 2014.  Each of these product lines has the possibility for broad market potential:  DCVax-L potentially for all or most types of operable solid tumors (i.e., tumors in any tissue of the body, which can be surgically removed) and DCVax-Direct potentially for all or most inoperable solid tumors (i.e., tumors in any tissues, which cannot be surgically removed).  NW Bio has also painstakingly built its operations on two continents, in both the US and Europe – including
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Icahn Responds To Forest Labs Board
2. iMD Companies responds to shareholder questions
3. Concord Medical Responds to Unusual Market Activity in its Stock
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Medbox Responds to Unprecedented Rise in Stock Price
6. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
7. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
8. Takeda Responds to Verdict in Diabetes Drug Case
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. Royalty Pharma Responds To Elans Tysabri Valuation
11. Inovio Pharmaceuticals Responds to Market Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BEDFORD, Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the ... City , New York on ... Interested parties are invited to listen to the live ... Hologic,s website at www.hologic.com/investors-overview . An archive of the ...
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire/ ... announced the submission of a Marketing Authorization ... (EMA) via the centralized procedure for talimogene ... adults with melanoma that is regionally or ... immunotherapy administered as an intralesional injection that ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6
... LAKES, N.J. , May 11 Nearly ... (LABAs) alone, and not in combination with other asthma ... and Drug Administration (FDA) on the risk of worsening ... according to a new study from the Medco ...
... May 11 Ethicon Endo-Surgery ... of surgical devices, the HARMONIC FOCUS® Long Curved Shears, ... that require deep access. The HARMONIC FOCUS® Long Curved ... using precise ultrasonic energy that minimizes thermal damage to ...
Cached Medicine Technology:Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 2Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 3Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 4Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations 5Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access 2
(Date:9/2/2014)... (PRWEB) September 02, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical ... market is expected to grow to over ... by an increase in the number of procedures ... kidney stones. This market includes TURP devices, laser ...
(Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
(Date:9/2/2014)... Dallas, TX (PRWEB) September 02, 2014 On ... annual family health and fitness fair ¡Vive tu vida! Get ... and good nutrition for better health and wellness for people ... free and open to the public, will be held at ... from 8:00 am to 1:00 pm. , “Since 2007, ...
(Date:9/2/2014)... 2014 Durable Medical Goods manufacture ... leasing and financing company LeaseQ, Inc. to help customers ... Since late 2012, LeaseQ’s breakthrough finance shopping platform has ... they need to run their business. , Said ... enable the ThermoTek sales team to provide customers faster ...
(Date:9/2/2014)... 02, 2014 The American Healthcare Documentation ... Free-Tuition Guarantee for its ICD-10 Medical Coding Bridge Program. ... highest level of confidence to students who are seeking ... but are faced with the uncertainty brought on by ... ICD-10 until October 1st, 2015. , AHDPG’s Free-Tuition Guarantee ...
Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3
... January is Thyroid Awareness Month , JACKSONVILLE, Fla. , ... and feel our best. Yet many never realize that one of ... just below the neck.   , The thyroid is a small, ... affect the function of many of the body,s organs including the ...
... 2010 - Chronic and severely stressful situations, like those ... associated with smaller volumes in "stress sensitive" brain regions, ... and the hippocampus, a brain region involved in memory ... Biological Psychiatry , suggests that chronic insomnia may ...
... 27, 2010) Researchers at Tufts University School of Medicine ... have developed a new tool for gene therapy that significantly ... other carriers and DNA alone, according to a study published ... Medicine . The tool, a peptide called PEG-POD, provides a ...
... to delay lactation in new moms, researchers find , ... class of antidepressants can cause delayed lactation in new ... order to breast-feed their babies, a new study says. ... reuptake inhibitors (SSRIs), which include such drugs as Prozac ...
... ... ... recognition of cervical cancer awareness month, Debra Macki , one of the industry’s most ... of this preventable cancer. The palette includes three shades that represent the three tools women ...
... ... Payment Platform for Utah’s Answer to Health Care Reform , ... Salt Lake City, UT (Vocus) January 27, ... by the State of Utah to provide payment-processing solutions and HSA administration for the ...
Cached Medicine News:Health News:Unlocking the Secrets to a Healthier Body 2Health News:Unlocking the Secrets to a Healthier Body 3Health News:Losing sleep, losing brain? 2Health News:Researchers develop new tool for gene delivery 2Health News:Antidepressants May Complicate Breast-Feeding 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 2Health News:Celebrity Make-Up Artist Introduces New Eye Shadow Palette for Cervical Cancer Awareness 3Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 2Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: